Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Sepsis: Personalized Medicine Utilizing 'Omic' Technologies-A Paradigm Shift?

Research output: Contribution to journalReviewResearchpeer-review

  1. Acute Lung Injury in Critically Ill Patients: Actin-Scavenger Gelsolin Signals Prolonged Respiratory Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mortality in critical illness: The impact of asymmetric dimethylarginine on survival-A systematic review and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Sepsis has over the years proven a considerable challenge to physicians and researchers. Numerous pharmacological and non-pharmacological interventions have been tested in trials, but have unfortunately failed to improve the general prognosis. This has led to the speculation that the sepsis population may be too heterogeneous to be targeted with the traditional one treatment suits all' approach. Recent advances in genetic and biochemical analyses now allow genotyping and biochemical characterisation of large groups of patients via the 'omics' technologies. These new opportunities could lead to a paradigm shift in the approach to sepsis towards personalised treatments with interventions targeted towards specific pathophysiological mechanisms activated in the patient. In this article, we review the potentials and pitfalls of using new advanced technologies to deepen our understanding of the clinical syndrome of sepsis.

Original languageEnglish
JournalHealthcare (Basel, Switzerland)
Issue number3
Pages (from-to)E111
Publication statusPublished - 7 Sep 2018

ID: 56537369